A Phase I Single Site, Single Dose, Randomised, Double-blind, Placebo Controlled 3-way Cross-over Biomarker Study Investigating the Effect of the GABA Modulator AZD7325 on Short Interval Intracortical Inhibition (SICI) in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2015
At a glance
- Drugs AZD 7325 (Primary)
- Indications Dystonia
- Focus Pharmacodynamics
- 27 Aug 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 12 Aug 2015 Planned primary completion date changed from 1 May 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.
- 21 Sep 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.